Show simple item record

dc.contributor.authorDillon, MTen_US
dc.contributor.authorBoylan, Zen_US
dc.contributor.authorSmith, Den_US
dc.contributor.authorGuevara, Jen_US
dc.contributor.authorMohammed, Ken_US
dc.contributor.authorPeckitt, Cen_US
dc.contributor.authorSaunders, Men_US
dc.contributor.authorBanerji, Uen_US
dc.contributor.authorClack, Gen_US
dc.contributor.authorSmith, SAen_US
dc.contributor.authorSpicer, JFen_US
dc.contributor.authorForster, MDen_US
dc.contributor.authorHarrington, KJen_US
dc.coverage.spatialIrelanden_US
dc.date.accessioned2018-08-09T10:45:09Z
dc.date.issued2018-08en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30073210en_US
dc.identifierS2405-6308(18)30049-1en_US
dc.identifier.citationClin Transl Radiat Oncol, 2018, 12 pp. 16 - 20en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2311
dc.identifier.eissn2405-6308en_US
dc.identifier.doi10.1016/j.ctro.2018.06.001en_US
dc.description.abstractPATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.en_US
dc.format.extent16 - 20en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectATR inhibitionen_US
dc.subjectClinical trialen_US
dc.subjectDNA damage responseen_US
dc.subjectPhase Ien_US
dc.subjectRadiosensitizationen_US
dc.titlePATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-06-06en_US
rioxxterms.versionofrecord10.1016/j.ctro.2018.06.001en_US
rioxxterms.licenseref.startdate2018-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClin Transl Radiat Oncolen_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished onlineen_US
pubs.volume12en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamClinical Pharmacology – Adaptive Therapyen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US
dc.contributor.icrauthorBanerji, Udaien_US
dc.contributor.icrauthorDillon, Magnusen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/